Year archive

Antengene Corporation Limited — 2023 filings

All 39 regulatory filings released by Antengene Corporation Limited (6996) in 2023, sourced directly from the official regulator.

39 Filings

2023 Period

2023 filings (39)

Filing	Released	Lang
VOLUNTARY ANNOUNCEMENT SELINEXOR (XPOVIO), ANTENGENE'S FIRST-IN-CLASS NEW DRUG, SUCCESSFULLY INCLUDED IN 2023 NATIONAL REIMBURSEMENT DRUG LIST Regulatory Filings	2023-12-13	English
VOLUNTARY ANNOUNCEMENT APPROVAL OF NDA BY THE PHARMACEUTICAL ADMINISTRATION BUREAU OF MACAU FOR ATG-010 (SELINEXOR) FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA Regulatory Filings	2023-12-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023 Share Issue/Capital Change	2023-12-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023 Regulatory Filings	2023-11-03	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023 Regulatory Filings	2023-10-05	English
NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS Report Publication Announcement	2023-09-27	English
2023 INTERIM REPORT Interim / Quarterly Report H1 2023	2023-09-27	English
VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENT Regulatory Filings	2023-09-18	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023 Regulatory Filings	2023-09-05	English
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 Interim / Quarterly Report H1 2023	2023-08-25	English
NOTICE OF DATE OF BOARD MEETING Regulatory Filings	2023-08-15	English
INSIDE INFORMATION COLLABORATION AGREEMENT BETWEEN ANTENGENE AND HANSOH PHARMA FOR THE COMMERCIALIZATION OF XPOVIO (SELINEXOR) IN THE MAINLAND OF CHINA Capital/Financing Update	2023-08-11	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023 Regulatory Filings	2023-08-03	English
VOLUNTARY ANNOUNCEMENT APPROVAL OF NDA BY THE HONG KONG DEPARTMENT OF HEALTH FOR ATG-010 (SELINEXOR) FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA Regulatory Filings	2023-07-17	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023 Regulatory Filings	2023-07-06	English
SEVENTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION Governance Information	2023-06-16	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 16, 2023 Declaration of Voting Results & Voting Rights Announcements	2023-06-16	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2023 Regulatory Filings	2023-06-06	English
VOLUNTARY ANNOUNCEMENT U.S. FDA IND CLEARANCE FOR THE PHASE I PERFORM TRIAL OF ATG-031 IN PATIENTS WITH ADVANCED SOLID TUMORS OR B-NHL Regulatory Filings	2023-05-18	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023 Regulatory Filings	2023-05-05	English
NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS Report Publication Announcement	2023-04-25	English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING AGM Information	2023-04-25	English
NOTICE OF THE ANNUAL GENERAL MEETING AGM Information	2023-04-25	English
(1) PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND TO REPURCHASE SHARES, (2) RE-ELECTION OF DIRECTORS, (3) RE-APPOINTMENT OF AUDITOR, (4) PROPOSED AMENDMENTS TO THE SIXTH AMENDED AND RESTATED MEMO AGM Information	2023-04-25	English
2022 ANNUAL REPORT Annual Report FY 2022	2023-04-25	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Board/Management Information	2023-04-14	English
CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR CHANGE IN COMPOSITION OF BOARD COMMITTEES AND ESTABLISHMENT OF THE SCIENTIFIC COMMITTEE Board/Management Information	2023-04-14	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2023 Regulatory Filings	2023-04-11	English
Remuneration Committee - Terms of Reference Remuneration Information	2023-03-29	English
PROPOSED AMENDMENTS TO THE SIXTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION AND THE ADOPTION OF THE SEVENTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION Regulatory Filings	2023-03-29	English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2022 Earnings Release FY 2022	2023-03-28	English
NOTICE OF DATE OF BOARD MEETING Regulatory Filings	2023-03-15	English
VOLUNTARY ANNOUNCEMENT IND APPROVAL FOR THE PHASE I CLINCH TRIAL OF ATG-022 FOR THE TREATMENT OF ADVANCED OR METASTATIC SOLID TUMORS IN CHINA Regulatory Filings	2023-03-13	English
VOLUNTARY ANNOUNCEMENT Regulatory Filings	2023-03-12	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2023 Share Issue/Capital Change	2023-03-03	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023 Share Issue/Capital Change	2023-02-03	English
VOLUNTARY ANNOUNCEMENT ACKNOWLEDGEMENT OF CTN BY THE TGA FOR PHASE I CLINICAL TRIAL OF ATG-022 IN ADVANCED OR METASTATIC SOLID TUMORS Regulatory Filings	2023-02-01	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022 Regulatory Filings	2023-01-05	English
VOLUNTARY ANNOUNCEMENT ENTERING INTO ASSIGNMENT AGREEMENT WITH CALITHERA BIOSCIENCES, INC. TO ACQUIRE ALL OUTSTANDING RIGHTS OF ATG-037 Capital/Financing Update	2023-01-04	English